{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:18:28Z","timestamp":1793643508493,"version":"4.5.1"},"reference-count":167,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1523,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiogenic shock (CS) is a complex multifactorial clinical syndrome, developing as a continuum, and progressing from the initial insult (underlying cause) to the subsequent occurrence of organ failure and death. There is a large phenotypic variability in CS, as a result of the diverse aetiologies, pathogenetic mechanisms, haemodynamics, and stages of severity. Although early revascularization remains the most important intervention for CS in settings of acute myocardial infarction, the administration of timely and effective antithrombotic therapy is critical to improving outcomes in these patients. In addition, other clinical settings or non-acute myocardial infarction aetiologies, associated with high thrombotic risk, may require specific regimens of short-term or long-term antithrombotic therapy. In CS, altered tissue perfusion, inflammation, and multi-organ dysfunction induce unpredictable alterations to antithrombotic drugs' pharmacokinetics and pharmacodynamics. Other interventions used in the management of CS, such as mechanical circulatory support, renal replacement therapies, or targeted temperature management, influence both thrombotic and bleeding risks and may require specific antithrombotic strategies. In order to optimize safety and efficacy of these therapies in CS, antithrombotic management should be more adapted to CS clinical scenario or specific device, with individualized antithrombotic regimens in terms of type of treatment, dose, and duration. In addition, patients with CS require a close and appropriate monitoring of antithrombotic therapies to safely balance the increased risk of bleeding and thrombosis.<\/jats:p>","DOI":"10.1002\/ehf2.13643","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T05:34:54Z","timestamp":1634794494000},"page":"4717-4736","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Antithrombotic and Anticoagulation Therapies in Cardiogenic Shock: A Critical Review of the Published Literature"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-2877","authenticated-orcid":false,"given":"Razvan I.","family":"Radu","sequence":"first","affiliation":[{"name":"ICCU Department, Emergency Institute for Cardiovascular Diseases \u2018Prof. Dr. C.C. Iliescu\u2019 , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuvia","family":"Ben Gal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rabin Medical Center (Beilinson Campus), Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Abdelhamid","sequence":"additional","affiliation":[{"name":"Cardiology Department, Kasr Alainy School of Medicine, Cairo University , Cairo ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena-Laura","family":"Antohi","sequence":"additional","affiliation":[{"name":"ICCU Department, Emergency Institute for Cardiovascular Diseases \u2018Prof. Dr. C.C. Iliescu\u2019 , Bucharest ,","place":["Romania"]},{"name":"University for Medicine and Pharmacy \u2018Carol Davila\u2019 Bucharest , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, Civil Hospitals and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kaiser Permanente San Francisco Medical Center , San Francisco, CA ,","place":["USA"]},{"name":"Division of Research, Kaiser Permanente Northern California, Oakland , CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliviana","family":"Geavlete","sequence":"additional","affiliation":[{"name":"ICCU Department, Emergency Institute for Cardiovascular Diseases \u2018Prof. Dr. C.C. Iliescu\u2019 , Bucharest ,","place":["Romania"]},{"name":"University for Medicine and Pharmacy \u2018Carol Davila\u2019 Bucharest , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Lopatin","sequence":"additional","affiliation":[{"name":"Cardiology Centre, Volgograd Medical University , Volgograd ,","place":["Russian Federation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lyon","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Service, Royal Brompton Hospital and Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Miro","sequence":"additional","affiliation":[{"name":"Emergency Department, Hospital Cl\u00ednic de Barcelona, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, Cardiothoracic Department, Civil Hospitals; Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parissis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine; Vanderbilt University Medical Centre , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-3628","authenticated-orcid":false,"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"ICCU Department, Emergency Institute for Cardiovascular Diseases \u2018Prof. Dr. C.C. Iliescu\u2019 , Bucharest ,","place":["Romania"]},{"name":"University for Medicine and Pharmacy \u2018Carol Davila\u2019 Bucharest , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"2026012114190493100_ehf213643-bib-0001","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114190493100_ehf213643-bib-0002","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"key":"2026012114190493100_ehf213643-bib-0003","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ejhf.890","article-title":"Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114190493100_ehf213643-bib-0004","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ejhf.1492","article-title":"Acute heart failure congestion and perfusion status\u2014impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry","volume":"21","author":"Chioncel","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114190493100_ehf213643-bib-0005","first-page":"3032","article-title":"Impaired microcirculation predicts poor outcome of patients with acute myocardial infarction complicated by cardiogenic shock","volume":"31","author":"den Uil","year":"2010","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026012114190493100_ehf213643-bib-0006","first-page":"108","article-title":"Prognostic implications of microcirculatory perfusion versus macrocirculatory perfusion in cardiogenic shock: a CULPRIT-SHOCK substudy","volume":"9","author":"Wijntjens","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026012114190493100_ehf213643-bib-0007","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/00003246-200005000-00005","article-title":"Microvascular response in patients with cardiogenic shock","volume":"28","author":"Kirschenbaum","year":"2000","journal-title":"Crit Care Med"},{"key":"2026012114190493100_ehf213643-bib-0008","first-page":"13068","article-title":"High thrombus burden: a review of mechanisms and treatments","volume":"12","author":"Ren","year":"2019","journal-title":"Int J Clin Exp Med"},{"key":"2026012114190493100_ehf213643-bib-0009","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/bja\/aev163","article-title":"Microcirculatory dysfunction and resuscitation: why, when, and how","volume":"115","author":"Moore","year":"2015","journal-title":"Br J Anaesth"},{"key":"2026012114190493100_ehf213643-bib-0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcin.2016.11.059","article-title":"Management of no-reflow phenomenon in the catheterization laboratory","volume":"10","author":"Rezkalla","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"2026012114190493100_ehf213643-bib-0011","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/medicina57010059","article-title":"Multifactorial background for a low biological response to antiplatelet agents used in stroke prevention","volume":"57","author":"Wisniewski","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2026012114190493100_ehf213643-bib-0012","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/03009734.2014.918679","article-title":"Evaluation of inflammatory conditions associated with aspirin resistance","volume":"119","author":"Yalcinkaya","year":"2014","journal-title":"Ups J Med Sci"},{"key":"2026012114190493100_ehf213643-bib-0013","first-page":"187","article-title":"Gastrointestinal motility and prokinetics in the critically ill","volume":"13","author":"Chapman","year":"2007","journal-title":"Curr Opin Crit Care"},{"key":"2026012114190493100_ehf213643-bib-0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ehjcvp\/pvaa009","article-title":"Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"7","author":"Gorog","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026012114190493100_ehf213643-bib-0015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjcard.2006.10.040","article-title":"Microbiological profile of septic complication in patients with cardiogenic shock following acute myocardial infarction (from the SHOCK study)","volume":"99","author":"Kohsaka","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00392-010-0235-6","article-title":"Characteristics and clinical outcome of 458 patients with acute myocardial infarction requiring mechanical ventilation. Results of the BEAT registry of the ALKK-study group","volume":"100","author":"Kouraki","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0017","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1164\/rccm.201102-0331OC","article-title":"Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis","volume":"184","author":"Perbet","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012114190493100_ehf213643-bib-0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/SHK.0000000000000756","article-title":"Infectious complications and immune\/inflammatory response in cardiogenic shock patients: a prospective observational study","volume":"47","author":"Parenica","year":"2017","journal-title":"Shock"},{"key":"2026012114190493100_ehf213643-bib-0019","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7326\/0003-4819-149-9-200811040-00005","article-title":"Ten-year trends in the incidence and treatment of cardiogenic shock","volume":"149","author":"AMIS Plus Registry Investigators","year":"2008","journal-title":"Ann Intern Med"},{"key":"2026012114190493100_ehf213643-bib-0020","first-page":"760","volume-title":"Management of cardiogenic shock complicating myocardial infarction","author":"Mebazaa","year":"2018"},{"issue":"3 Suppl A","key":"2026012114190493100_ehf213643-bib-0021","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0735-1097(00)00879-2","article-title":"Cardiogenic shock complicating acute myocardial infarction\u2014etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock?","volume":"36","author":"Hochman","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0022","first-page":"924","article-title":"Technical consideration in acute myocardial infarction with cardiogenic shock: a review of antithrombotic and PCI therapies","volume":"95","author":"Marquis-Gravel","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026012114190493100_ehf213643-bib-0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"9","key":"2026012114190493100_ehf213643-bib-0024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock","volume":"341","author":"Hochman","year":"1999","journal-title":"New England J Med"},{"key":"2026012114190493100_ehf213643-bib-0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/hj.1999.v137.95352","article-title":"SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA\/CABG-trial design. The SHOCK Trial Study Group","volume":"137","author":"Hochman","year":"1999","journal-title":"Am Heart J"},{"key":"2026012114190493100_ehf213643-bib-0026","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.295.21.2511","article-title":"Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction","author":"Hochman","year":"2006","journal-title":"Jama"},{"key":"2026012114190493100_ehf213643-bib-0027","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1067\/mhj.2001.115294","article-title":"Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry","volume":"141","author":"Webb","year":"2001","journal-title":"Am Heart J"},{"key":"2026012114190493100_ehf213643-bib-0028","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2459\/JCM.0000000000000106","article-title":"Drug-eluting stents vs. bare metal stents in patients with cardiogenic shock: a comparison by propensity score analysis","volume":"16","author":"Jaguszewski","year":"2015","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026012114190493100_ehf213643-bib-0029","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","article-title":"PCI strategies in patients with acute myocardial infarction and cardiogenic shock","volume":"377","author":"Thiele","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114190493100_ehf213643-bib-0030","doi-asserted-by":"crossref","DOI":"10.1161\/HCV.0000000000000035","article-title":"An update on radial artery access and best practices for transradial coronary angiography and intervention in acute coronary syndrome: a scientific statement from the American Heart Association","volume":"11","author":"Mason","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2026012114190493100_ehf213643-bib-0031","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00134-018-5214-9","article-title":"Management of cardiogenic shock complicating myocardial infarction","volume":"44","author":"Mebazaa","year":"2018","journal-title":"Intensive Care Med"},{"key":"2026012114190493100_ehf213643-bib-0032","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"key":"2026012114190493100_ehf213643-bib-0033","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(11)60404-2","article-title":"Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial","volume":"377","author":"Jolly","year":"2011","journal-title":"Lancet"},{"key":"2026012114190493100_ehf213643-bib-0034","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2012.06.017","article-title":"Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study","volume":"60","author":"Romagnoli","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0035","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11239-014-1133-y","article-title":"Comparison of radial to femoral PCI in acute myocardial infarction and cardiogenic shock: a systematic review","volume":"40","author":"Gandhi","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"2026012114190493100_ehf213643-bib-0036","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ahj.2015.05.001","article-title":"Impact of access site choice on outcomes of patients with cardiogenic shock undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"170","author":"Pancholy","year":"2015","journal-title":"Am Heart J"},{"key":"2026012114190493100_ehf213643-bib-0037","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2019.4852","article-title":"Safety and efficacy of femoral access vs radial access in ST-segment elevation myocardial infarction: the SAFARI-STEMI randomized clinical trial","volume":"5","author":"le May","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0038","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/eurheartj\/ehaa909","article-title":"Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation","volume":"42","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114190493100_ehf213643-bib-0039","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMoa1415098","article-title":"Randomized trial of primary PCI with or without routine manual thrombectomy","volume":"372","author":"Jolly","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012114190493100_ehf213643-bib-0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1067\/mhj.2001.112681","article-title":"Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: results from the MITRA and MIR studies","volume":"141","author":"Frilling","year":"2001","journal-title":"Am Heart J"},{"key":"2026012114190493100_ehf213643-bib-0041","article-title":"Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis","volume":"97","author":"Hu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026012114190493100_ehf213643-bib-0042","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"Wurtz","year":"2010","journal-title":"Heart"},{"key":"2026012114190493100_ehf213643-bib-0043","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.ijcard.2012.05.080","article-title":"Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial","volume":"167","author":"Parri","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0044","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001952","article-title":"Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients: the ADAPT-DES study","volume":"8","author":"Weisz","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2026012114190493100_ehf213643-bib-0045","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593","article-title":"Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"8","author":"Parodi","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2026012114190493100_ehf213643-bib-0046","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0047","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/eci.12550","article-title":"Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers","volume":"46","author":"Hobl","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"2026012114190493100_ehf213643-bib-0048","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025232","article-title":"Morphine in acute coronary syndrome: systematic review and meta-analysis","volume":"9","author":"Duarte","year":"2019","journal-title":"BMJ Open"},{"key":"2026012114190493100_ehf213643-bib-0049","first-page":"267","article-title":"Emerging role of fentanyl in antiplatelet therapy","volume":"76","author":"Kuczynska","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114190493100_ehf213643-bib-0050","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1055\/s-0038-1666862","article-title":"Fentanyl delays the platelet inhibition effects of oral ticagrelor: full report of the PACIFY randomized clinical trial","volume":"118","author":"Ibrahim","year":"2018","journal-title":"Thromb Haemost"},{"key":"2026012114190493100_ehf213643-bib-0051","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"2026012114190493100_ehf213643-bib-0052","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"2026012114190493100_ehf213643-bib-0053","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: a global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"key":"2026012114190493100_ehf213643-bib-0054","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","article-title":"Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap","volume":"170","author":"Alexopoulos","year":"2015","journal-title":"Am Heart J"},{"key":"2026012114190493100_ehf213643-bib-0055","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0056","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719893274","article-title":"Intravenous antiplatelet therapies (glycoprotein IIb\/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use","volume":"13","author":"Capodanno","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026012114190493100_ehf213643-bib-0057","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0058","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamacardio.2016.4556","article-title":"Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb\/IIIa inhibitors: an exploratory analysis from the CHAMPION trials","volume":"2","author":"Vaduganathan","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0059","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"2026012114190493100_ehf213643-bib-0060","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"2026012114190493100_ehf213643-bib-0061","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/09537104.2015.1069809","article-title":"Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro","volume":"27","author":"Judge","year":"2016","journal-title":"Platelets"},{"key":"2026012114190493100_ehf213643-bib-0062","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcin.2016.10.004","article-title":"Randomized comparison of oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor: the ExcelsiorLOAD2 trial","volume":"10","author":"Hochholzer","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2026012114190493100_ehf213643-bib-0063","first-page":"1","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)","volume":"20","author":"Neumann","year":"2019","journal-title":"G Ital Cardiol (Rome)"},{"key":"2026012114190493100_ehf213643-bib-0064","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"key":"2026012114190493100_ehf213643-bib-0065","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/ehq143","article-title":"Use of glycoprotein IIb\/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial","volume":"31","author":"Huber","year":"2010","journal-title":"Eur Heart J"},{"key":"2026012114190493100_ehf213643-bib-0066","first-page":"1576","article-title":"Routine glycoprotein IIb\/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis","volume":"35","author":"Karathanos","year":"2019","journal-title":"Can J Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0067","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0039-1700546","article-title":"Efficacy and safety of glycoprotein IIb\/IIIa inhibitors on top of ticagrelor in STEMI: a subanalysis of the ATLANTIC trial","volume":"120","author":"Tavenier","year":"2020","journal-title":"Thromb Haemost"},{"key":"2026012114190493100_ehf213643-bib-0068","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/17482941.2011.567282","article-title":"Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: the PRAGUE-7 Study. An open randomized multicentre study","volume":"13","author":"Tousek","year":"2011","journal-title":"Acute Card Care"},{"key":"2026012114190493100_ehf213643-bib-0069","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40560-020-00502-y","article-title":"Glycoprotein IIb\/IIIa inhibitors for cardiogenic shock complicating acute myocardial infarction: a systematic review, meta-analysis, and meta-regression","volume":"8","author":"Saleiro","year":"2020","journal-title":"J Intensive Care"},{"key":"2026012114190493100_ehf213643-bib-0070","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1570161116666180117102422","article-title":"What is the role for glycoprotein IIb\/IIIa inhibitor use in the catheterization laboratory in the current era?","volume":"16","author":"Rubboli","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"2026012114190493100_ehf213643-bib-0071","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jcin.2010.09.015","article-title":"The evolving role of glycoprotein IIb\/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes","volume":"3","author":"Hanna","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"2026012114190493100_ehf213643-bib-0072","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1160\/TH06-05-0290","article-title":"Monitoring unfractionated heparin with the aPTT: time for a fresh look","volume":"96","author":"Eikelboom","year":"2006","journal-title":"Thromb Haemost"},{"key":"2026012114190493100_ehf213643-bib-0073","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0038-1677018","article-title":"How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors","volume":"45","author":"Favaloro","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"2026012114190493100_ehf213643-bib-0074","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","article-title":"Establishing a therapeutic range for heparin therapy","volume":"119","author":"Brill-Edwards","year":"1993","journal-title":"Ann Intern Med"},{"key":"2026012114190493100_ehf213643-bib-0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5045\/br.2016.51.3.171","article-title":"Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy","volume":"51","author":"Byun","year":"2016","journal-title":"Blood Res"},{"key":"2026012114190493100_ehf213643-bib-0076","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/01.CIR.0000077530.53367.E9","article-title":"Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"key":"2026012114190493100_ehf213643-bib-0077","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/B:THRO.0000037667.52940.64","article-title":"Establishing a new target range for unfractionated heparin for acute coronary syndromes","volume":"17","author":"Lee","year":"2004","journal-title":"J Thromb Thrombolysis"},{"key":"2026012114190493100_ehf213643-bib-0078","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1345\/aph.1Q161","article-title":"Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion","volume":"45","author":"Guervil","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2026012114190493100_ehf213643-bib-0079","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"key":"2026012114190493100_ehf213643-bib-0080","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/jcpt.12415","article-title":"Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study","volume":"41","author":"Samuel","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"2026012114190493100_ehf213643-bib-0081","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"Smythe","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2026012114190493100_ehf213643-bib-0082","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619876030","article-title":"Evaluation of antifactor-Xa heparin assay and activated partial thromboplastin time values in patients on therapeutic continuous infusion unfractionated heparin therapy","volume":"25","author":"McLaughlin","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026012114190493100_ehf213643-bib-0083","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.amjcard.2019.08.013","article-title":"Mechanical circulatory support in transcatheter aortic valve implantation in the United States (from the National Inpatient Sample)","volume":"124","author":"Alkhalil","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0084","doi-asserted-by":"crossref","first-page":"g7566","DOI":"10.1136\/bmj.g7566","article-title":"Heparin induced thrombocytopenia","volume":"350","author":"Linkins","year":"2015","journal-title":"BMJ"},{"key":"2026012114190493100_ehf213643-bib-0085","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","article-title":"Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study","volume":"125","author":"Kang","year":"2015","journal-title":"Blood"},{"key":"2026012114190493100_ehf213643-bib-0086","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.resuscitation.2017.10.019","article-title":"Early coronary angiography in patients resuscitated from out of hospital cardiac arrest without ST-segment elevation: a systematic review and meta-analysis","volume":"121","author":"Khan","year":"2017","journal-title":"Resuscitation"},{"key":"2026012114190493100_ehf213643-bib-0087","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13613-018-0366-x","article-title":"Impaired aspirin-mediated platelet function inhibition in resuscitated patients with acute myocardial infarction treated with therapeutic hypothermia: a prospective, observational, non-randomized single-centre study","volume":"8","author":"Pr\u00fcller","year":"2018","journal-title":"Ann Intensive Care"},{"key":"2026012114190493100_ehf213643-bib-0088","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1097\/CCM.0b013e3181aa5241","article-title":"Mechanisms of action, physiological effects, and complications of hypothermia","volume":"37","author":"Polderman","year":"2009","journal-title":"Crit Care Med"},{"key":"2026012114190493100_ehf213643-bib-0089","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/1573403X14666180507154849","article-title":"Targeted temperature management; review of literature and guidelines; a cardiologist's perspective","volume":"14","author":"Hashim","year":"2018","journal-title":"Curr Cardiol Rev"},{"key":"2026012114190493100_ehf213643-bib-0090","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.resuscitation.2014.02.013","article-title":"Stent thrombosis: an increased adverse event after angioplasty following resuscitated cardiac arrest","volume":"85","author":"Joffre","year":"2014","journal-title":"Resuscitation"},{"key":"2026012114190493100_ehf213643-bib-0091","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2013.09.028","article-title":"Is therapeutic hypothermia a risk factor for stent thrombosis?","volume":"63","author":"Rosillo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0092","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.resuscitation.2016.02.012","article-title":"Clopidogrel pharmacokinetics and pharmacodynamics in out-of-hospital cardiac arrest patients with acute coronary syndrome undergoing target temperature management","volume":"102","author":"Kaufmann","year":"2016","journal-title":"Resuscitation"},{"key":"2026012114190493100_ehf213643-bib-0093","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.resuscitation.2014.01.028","article-title":"A systematic review and pooled analysis of CPR-associated cardiovascular and thoracic injuries","volume":"85","author":"Miller","year":"2014","journal-title":"Resuscitation"},{"key":"2026012114190493100_ehf213643-bib-0094","doi-asserted-by":"crossref","first-page":"113","DOI":"10.15420\/icr.2019.3.2","article-title":"Contemporary management of out-of-hospital cardiac arrest in the cardiac catheterisation laboratory: current status and future directions","volume":"14","author":"Pareek","year":"2019","journal-title":"Interv Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.resuscitation.2016.04.027","article-title":"Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest resuscitation","volume":"105","author":"Llitjos","year":"2016","journal-title":"Resuscitation"},{"key":"2026012114190493100_ehf213643-bib-0096","first-page":"1396","article-title":"Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia","volume":"30","author":"Moudgil","year":"2014","journal-title":"Can J Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0097","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.116.024872","article-title":"Ticagrelor versus clopidogrel in comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention and hypothermia: a randomized study","volume":"134","author":"Steblovnik","year":"2016","journal-title":"Circulation"},{"key":"2026012114190493100_ehf213643-bib-0098","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1753944713487781","article-title":"Update on platelet glycoprotein IIb\/IIIa inhibitors: recommendations for clinical practice","volume":"7","author":"Muniz-Lozano","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026012114190493100_ehf213643-bib-0099","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jcin.2015.04.031","article-title":"Impact of glycoprotein IIb\/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the National Cardiovascular Data Registry","volume":"8","author":"Safley","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2026012114190493100_ehf213643-bib-0100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.resuscitation.2013.12.014","article-title":"Heparin dosing in critically ill patients undergoing therapeutic hypothermia following cardiac arrest","volume":"85","author":"Wahby","year":"2014","journal-title":"Resuscitation"},{"key":"2026012114190493100_ehf213643-bib-0101","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.resuscitation.2016.06.031","article-title":"Safety of glycoprotein IIb\/IIIa inhibitors in patients under therapeutic hypothermia admitted for an acute coronary syndrome","volume":"106","author":"Jim\u00e9nez-Br\u00edtez","year":"2016","journal-title":"Resuscitation"},{"key":"2026012114190493100_ehf213643-bib-0102","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00134-019-05897-3","article-title":"Why we need safer anticoagulant strategies for patients on short-term percutaneous mechanical circulatory support","volume":"46","author":"Vandenbriele","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026012114190493100_ehf213643-bib-0103","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s00134-018-5346-y","article-title":"Prevalence and outcome of heparin-induced thrombocytopenia diagnosed under veno-arterial extracorporeal membrane oxygenation: a retrospective nationwide study","volume":"44","author":"Kimmoun","year":"2018","journal-title":"Intensive Care Med"},{"key":"2026012114190493100_ehf213643-bib-0104","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1160\/TH16-03-0230","article-title":"Heparin-induced thrombocytopenia in cardiac surgery and critically ill patients","volume":"116","author":"Selleng","year":"2016","journal-title":"Thromb Haemost"},{"key":"2026012114190493100_ehf213643-bib-0105","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00134-018-5465-5","article-title":"Focus on extracorporeal life support","volume":"44","author":"Schellongowski","year":"2018","journal-title":"Intensive Care Med"},{"key":"2026012114190493100_ehf213643-bib-0106","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MAT.0000000000000811","article-title":"Impact of anticoagulation and circuit technology on complications during extracorporeal membrane oxygenation","volume":"65","author":"Niebler","year":"2019","journal-title":"ASAIO J"},{"key":"2026012114190493100_ehf213643-bib-0107","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MAT.0000000000001004","article-title":"Evaluation of anti-Xa and activated partial thromboplastin time monitoring of heparin in adult patients receiving extracorporeal membrane oxygenation support","volume":"66","author":"Arnouk","year":"2020","journal-title":"ASAIO J"},{"key":"2026012114190493100_ehf213643-bib-0108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.21037\/acs.2018.07.03","article-title":"Traditional and non-traditional anticoagulation management during extracorporeal membrane oxygenation","volume":"8","author":"Koster","year":"2019","journal-title":"Ann Cardiothorac Surg"},{"key":"2026012114190493100_ehf213643-bib-0109","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ejcts\/ezz098","article-title":"2019 EACTS expert consensus on long-term mechanical circulatory support","volume":"56","author":"Potapov","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026012114190493100_ehf213643-bib-0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/ejcts\/ezx325","article-title":"2017 EACTS\/EACTA Guidelines on patient blood management for adult cardiac surgery","volume":"53","author":"Pagano","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026012114190493100_ehf213643-bib-0111","doi-asserted-by":"crossref","first-page":"521","DOI":"10.21037\/atm-20-4849","article-title":"Antiplatelet and anticoagulation strategies for left ventricular assist devices","volume":"9","author":"Loyaga-Rendon","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026012114190493100_ehf213643-bib-0112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.healun.2012.09.013","article-title":"The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary","volume":"32","author":"Feldman","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"2026012114190493100_ehf213643-bib-0113","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.healun.2013.10.009","article-title":"Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation","volume":"33","author":"Sandner","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"2026012114190493100_ehf213643-bib-0114","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"2026012114190493100_ehf213643-bib-0115","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2327","article-title":"Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary","author":"Ben Gal","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114190493100_ehf213643-bib-0116","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijcard.2015.03.162","article-title":"Mortality in takotsubo syndrome is similar to mortality in myocardial infarction\u2014a report from the SWEDEHEART registry","volume":"185","author":"Redfors","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bpa.2017.08.005","article-title":"Renal replacement therapy and anticoagulation","volume":"31","author":"Brandenburger","year":"2017","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"2026012114190493100_ehf213643-bib-0118","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med"},{"key":"2026012114190493100_ehf213643-bib-0119","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1592\/phco.27.10.1347","article-title":"Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety","volume":"27","author":"Lachish","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2026012114190493100_ehf213643-bib-0120","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2021","author":"McDonagh","journal-title":"Eur Heart J"},{"key":"2026012114190493100_ehf213643-bib-0121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcmg.2013.09.020","article-title":"Echocardiographic correlates of acute heart failure, cardiogenic shock, and in-hospital mortality in tako-tsubo cardiomyopathy","volume":"7","author":"Citro","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114190493100_ehf213643-bib-0122","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ejhf.424","article-title":"Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology","volume":"18","author":"Lyon","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114190493100_ehf213643-bib-0123","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ejhf.1698","article-title":"Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry","volume":"22","author":"D'Ascenzo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114190493100_ehf213643-bib-0124","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/j.ijcard.2008.12.208","article-title":"Incidence and treatment of left ventricular apical thrombosis in Tako-tsubo cardiomyopathy","volume":"146","author":"Kurisu","year":"2011","journal-title":"Int J Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0125","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.119.043716","article-title":"Left ventricular noncompaction and cardiogenic shock","volume":"141","author":"Kazmirczak","year":"2020","journal-title":"Circulation"},{"key":"2026012114190493100_ehf213643-bib-0126","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015563","article-title":"Long-term survival of patients with left ventricular noncompaction","volume":"10","author":"Vaidya","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026012114190493100_ehf213643-bib-0127","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1074248418783745","article-title":"Anticoagulation therapy in specific cardiomyopathies: isolated left ventricular noncompaction and peripartum cardiomyopathy","volume":"24","author":"Kido","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012114190493100_ehf213643-bib-0128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4065\/72.1.26","article-title":"Isolated noncompaction of the myocardium in adults","volume":"72","author":"Ritter","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"2026012114190493100_ehf213643-bib-0129","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0735-1097(00)00755-5","article-title":"Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis","volume":"36","author":"Oechslin","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000082050","article-title":"Left ventricular hypertrabeculation\/noncompaction and stroke or embolism","volume":"103","author":"Stollberger","year":"2005","journal-title":"Cardiology"},{"key":"2026012114190493100_ehf213643-bib-0131","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5172308","article-title":"The current approach to diagnosis and management of left ventricular noncompaction cardiomyopathy: review of the literature","volume":"2016","author":"Bennett","year":"2016","journal-title":"Cardiol Res Pract"},{"key":"2026012114190493100_ehf213643-bib-0132","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.283.9.1183","article-title":"Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review","volume":"283","author":"Pearson","year":"2000","journal-title":"JAMA"},{"key":"2026012114190493100_ehf213643-bib-0133","article-title":"Peripartum cardiomyopathy","volume":"364","author":"Honigberg","year":"2019","journal-title":"BMJ"},{"key":"2026012114190493100_ehf213643-bib-0134","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamacardio.2017.3605","article-title":"Poor outcomes in poor patients?: peripartum cardiomyopathy\u2014not just black and white","volume":"2","author":"Bauersachs","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0135","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamacardio.2017.3574","article-title":"Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and non-African American women","volume":"2","author":"Irizarry","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0136","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001056","article-title":"Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study","volume":"3","author":"Kolte","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026012114190493100_ehf213643-bib-0137","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114190493100_ehf213643-bib-0138","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.1843","article-title":"Optimal antithrombotic regimen in patients with cardiogenic shock on Impella\u2122 mechanical support: less might be more","volume":"41","author":"Vandenbriele","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114190493100_ehf213643-bib-0139","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ejhf.586","article-title":"Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"18","author":"Bauersachs","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114190493100_ehf213643-bib-0140","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5603\/KP.2019.0049","article-title":"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy","volume":"77","author":"Regitz-Zagrosek","year":"2019","journal-title":"Kardiol Pol"},{"key":"2026012114190493100_ehf213643-bib-0141","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.amjcard.2010.09.013","article-title":"Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis","volume":"107","author":"Keuleers","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0142","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","article-title":"Prosthetic heart valve thrombosis","volume":"68","author":"Dangas","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0143","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/heartjnl-2017-311856","article-title":"Mechanical and surgical bioprosthetic valve thrombosis","volume":"103","author":"Lim","year":"2017","journal-title":"Heart"},{"key":"2026012114190493100_ehf213643-bib-0144","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"2026012114190493100_ehf213643-bib-0145","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"2021","author":"Vahanian","journal-title":"Eur Heart J"},{"key":"2026012114190493100_ehf213643-bib-0146","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/cc9057","article-title":"Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study","volume":"14","author":"Meierhenrich","year":"2010","journal-title":"Crit Care"},{"key":"2026012114190493100_ehf213643-bib-0147","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1540-8191.2005.2004123.x","article-title":"Risk factors of postoperative atrial fibrillation after cardiac surgery","volume":"20","author":"Auer","year":"2005","journal-title":"J Card Surg"},{"key":"2026012114190493100_ehf213643-bib-0148","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"2026012114190493100_ehf213643-bib-0149","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1001\/jama.291.14.1720","article-title":"A multicenter risk index for atrial fibrillation after cardiac surgery","volume":"291","author":"Mathew","year":"2004","journal-title":"JAMA"},{"key":"2026012114190493100_ehf213643-bib-0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1164\/rccm.200701-031OC","article-title":"Incidence and prognosis of sustained arrhythmias in critically ill patients","volume":"178","author":"Annane","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012114190493100_ehf213643-bib-0151","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ejhf.1153","article-title":"Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice","volume":"20","author":"Siliste","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114190493100_ehf213643-bib-0152","article-title":"Management of atrial fibrillation in critically ill patients","volume":"2014","author":"Arrigo","year":"2014","journal-title":"Crit Care Res Pract"},{"key":"2026012114190493100_ehf213643-bib-0153","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0140-6736(93)90274-K","article-title":"Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion","volume":"341","author":"Goldhaber","year":"1993","journal-title":"Lancet"},{"key":"2026012114190493100_ehf213643-bib-0154","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2014.5990","article-title":"Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis","volume":"311","author":"Chatterjee","year":"2014","journal-title":"JAMA"},{"key":"2026012114190493100_ehf213643-bib-0155","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01647-2019","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)","volume":"54","author":"Konstantinides","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012114190493100_ehf213643-bib-0156","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1093\/eurheartj\/ehy464","article-title":"Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases","volume":"39","author":"Meneveau","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114190493100_ehf213643-bib-0157","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1161\/CIRCRESAHA.120.317055","article-title":"COVID-19 and the heart","volume":"126","author":"Akhmerov","year":"2020","journal-title":"Circ Res"},{"key":"2026012114190493100_ehf213643-bib-0158","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","volume":"5","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0159","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMc2009020","article-title":"ST-segment elevation in patients with Covid-19\u2014a case series","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114190493100_ehf213643-bib-0160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jamacardio.2020.1096","article-title":"Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Inciardi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0161","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0162","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.recesp.2020.04.006","article-title":"Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology","volume":"73","author":"Vivas","year":"2020","journal-title":"Rev Esp Cardiol"},{"key":"2026012114190493100_ehf213643-bib-0163","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol"},{"key":"2026012114190493100_ehf213643-bib-0164","first-page":"postgradmedj-2021-139923","article-title":"Anticoagulation in COVID-19: current concepts and controversies","author":"Chandra","year":"2021","journal-title":"Postgrad Med J"},{"key":"2026012114190493100_ehf213643-bib-0165","volume-title":"Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health","author":"COVID-19 Treatment Guidelines Panel"},{"key":"2026012114190493100_ehf213643-bib-0166","volume-title":"Intermediate or prophylactic-dose anticoagulation for venous or arterial thromboembolism in severe COVID-19: a cluster based randomized selection trial (IMPROVE-COVID)"},{"key":"2026012114190493100_ehf213643-bib-0167","volume-title":"Anticoagulation in critically ill patients with COVID-19 (the IMPACT Trial) (IMPACT)"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13643","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13643","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/6\/4717\/65569185\/eschf_8_6_4717.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/6\/4717\/65569185\/eschf_8_6_4717.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:22:56Z","timestamp":1769023376000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/6\/4717\/8343674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":167,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,19]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13643","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"2021-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}